Начало › Рак на белия дроб с недребноклетъчен тип › Минесота › Rochester
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Rochester, MN
37 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Rochester (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Набиране на участнициФаза 1/2
- Mayo Clinic-Rochester /ID# 274512, Rochester
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 1/2
- Research Site, Rochester
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Набиране на участнициФаза 1
- Exelixis Clinical Site #68, Rochester
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Mayo Clinic in Rochester, Rochester
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Набиране на участнициФаза 3
- Mayo Clinic - Rochester ( Site 0073), Rochester
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Набиране на участнициФаза 3
- Mayo Clinic - Rochester ( Site 0148), Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Набиране на участнициНаблюдателно проучване
- Mayo Clinic Rochester, Rochester
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Mayo Clinic Rochester, Rochester
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Mayo Clinic, Rochester
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Mayo Clinic, Rochester
Pan-tumor MRD Study
Набиране на участнициНаблюдателно проучване
- Mayo Clinic, Rochester
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Research Site, Rochester
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Mayo Clinic, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Набиране на участнициНаблюдателно проучване
- Mayo Clinic (Rochester), Rochester
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Mayo Clinic, Rochester
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- Mayo Rochester, Rochester
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Набиране на участнициФаза 3
- Research Site, Rochester
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Набиране на участнициФаза 1
- Mayo Clinic, Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Набиране на участнициФаза 1
- Mayo Clinic - Rochester, Rochester
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- Mayo Clinic, Rochester
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Набиране на участнициФаза 1/2
- Mayo Clinic-Rochester, Rochester
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
Набиране на участнициЗдравите доброволци са добре дошли
- Mayo Clinic in Rochester, Rochester
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набиране на участнициФаза 3
- Mayo Clinic in Rochester, Rochester
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Набиране на участнициФаза 1/2
- Mayo Clinic Hospital - Rochester, MN, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Набиране на участнициФаза 1
- Mayo Clinic Rochester, Rochester
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Набиране на участнициФаза 1
- Mayo Clinic Cancer Center, Rochester
- Mayo Clinic, Rochester
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 3
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Набиране на участнициФаза 1/2
- Mayo Clinic Rochester, Rochester
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Набиране на участнициФаза 1
- Mayo Clinic Comprehensive Cancer Center, Rochester
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Набиране на участнициФаза 3
- Mayo Clinic, Rochester
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Mayo Clinic in Rochester, Rochester
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Набиране на участнициФаза 1/2
- Mayo Clinic Cancer Center, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Mayo Clinic, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Набиране на участнициНаблюдателно проучване
- Mayo Clinic in Rochester, Rochester
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Mayo Clinic (Data Collection Only), Rochester
Insomnia in Patients With Metastatic Lung Cancer
Набиране на участнициНаблюдателно проучване
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Набиране на участнициФаза 1/2
- Mayo Clinic, Rochester
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в Rochester
- Рак на гърдата42 проучвания
- Метастатичен рак31 проучвания
- Рак (всички видове)30 проучвания
- Рак на яйчниците29 проучвания
- Колоректален рак29 проучвания
- Множествен миелом24 проучвания
- Сърдечна недостатъчност22 проучвания
- Рак на простатата22 проучвания
- Рак на панкреаса22 проучвания
- Ендометриален рак20 проучвания
- Рак на белия дроб20 проучвания
- Хронична лимфоцитна левкемия18 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.